HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

WinHealth International Holding / Equity Capital Markets

<ul>
<li>By establishing a multi-engine BD model of "M&amp;A+licensing cooperation+CSO", WinHealth’s ability to identify and acquire innovative drugs and other high-quality assets with significant commercial potential is effectively enhanced.</li>
<li>Based on our forecast, high growth in 2025 is driven by the Kyowa Kyrin China Acquisition.In 2026-2027, Kapruvia is expected to drive the growth of WinHealth.However, revenue growth gradually declined. </li>
<li>Valuation should be lower than pure innovative drug companies (e.g. Innovent, Akeso, Kelun Bio, etc.), and CMS who has similar business model but more mature system and higher profit margin.</li>
</ul>


By establishing a multi-engine BD model of "M&amp;A+licensing cooperation+CSO", WinHealth’s ability to identify and acquire innovative drugs and other high-quality assets with significant commercial potential is effectively enhanced.
Based on our forecast, high growth in 2025 is driven by the Kyowa Kyrin China Acquisition.In 2026-2027, Kapruvia is expected to drive the growth of WinHealth.However, revenue growth gradually declined. 
Valuation should be lower than pure innovative drug companies (e.g. Innovent, Akeso, Kelun Bio, etc.), and CMS who has similar business model but more mature system and higher profit margin.


Pre-IPO WinHealth International Holding- A BD-Driven Model May Not Guarantee Sustainable High Growth

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Feb 6th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in Zto Express, HSBC, Hua Hong Semiconductor, Techtronic.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Feb 6th.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in Zto Express, HSBC, Hua Hong Semiconductor, Techtronic.


HK Short Interest Weekly: Zto Express, HSBC, Hua Hong Semiconductor, Techtronic

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 13th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Alibaba, Meituan, China Life, CNOOC.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 13th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Alibaba, Meituan, China Life, CNOOC.


HK Connect Flows Weekly (Feb 13th): Tencent, Alibaba, Meituan, China Life, CNOOC

Ming Yu Pharmaceutical / Equity Capital Markets

<ul>
<li>Almost all core pipelines of Ming Yu are facing fierce competition from domestic and foreign pharmaceutical giants, but Ming Yu has no commercialized products on the market. </li>
<li>In order to become a cornerstone drug of the generation, the key is not whether the molecule is the best, but whether Ming Yu has enough resources to drive R&amp;D</li>
<li>Ming Yu’s commercialization capability still needs to be verified. We think valuation of Ming Yu would be lower than peers such as Akeso and Kelun Bio.</li>
</ul>


Almost all core pipelines of Ming Yu are facing fierce competition from domestic and foreign pharmaceutical giants, but Ming Yu has no commercialized products on the market. 
In order to become a cornerstone drug of the generation, the key is not whether the molecule is the best, but whether Ming Yu has enough resources to drive R&amp;D
Ming Yu’s commercialization capability still needs to be verified. We think valuation of Ming Yu would be lower than peers such as Akeso and Kelun Bio.


Pre-IPO Ming Yu Pharmaceutical - Popular Products Do Not Necessarily Guarantee Commercial Success

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.</li>
<li>The official index changes and indicative weights for the March 2026 index rebal event will be announced publicly after the close on Friday 13th February 2026.</li>
<li>We continue to expect one index change for March 2026 and we estimate there to be capping flows of US$114mn one-way.</li>
</ul>


The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.
The official index changes and indicative weights for the March 2026 index rebal event will be announced publicly after the close on Friday 13th February 2026.
We continue to expect one index change for March 2026 and we estimate there to be capping flows of US$114mn one-way.


Quiddity Leaderboard HSCEI Mar26: One Index Change Likely; Announcement Soon

China

Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akeso (9926 HK)

Pre-IPO WinHealth International Holding- A BD-Driven Model May Not Guarantee Sustainable High Growth

WinHealth's multi-engine BD model boosts ability to acquire innovative drugs, with short -term growth driven by acquisitions of Kyowa Kyrin, but...

Xinyao (Criss) Wang

HK Short Interest Weekly: Zto Express, HSBC, Hua Hong Semiconductor, Techtronic

We analyzed the latest HK SFC report for aggregate short position as of Feb 6th and highlight short interest changes in Zto Express, HSBC, Hua Hong...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Feb 13th): Tencent, Alibaba, Meituan, China Life, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Alibaba, Meituan, China Life, CNOOC.

Ke Yan, CFA, FRM

Pre-IPO Ming Yu Pharmaceutical - Popular Products Do Not Necessarily Guarantee Commercial Success

All core pipelines of Ming Yu face fierce competition, without commercialized products on the market.Success hinges on R&D resources and...

Xinyao (Criss) Wang

Quiddity Leaderboard HSCEI Mar26: One Index Change Likely; Announcement Soon

We see China Mengniu Dairy Co (2319 HK) as a high-conviction DEL and Horizon Robotics (9660 HK) as the replacement ADD in March 2026.

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO WinHealth International Holding- A BD-Driven Model May Not Guarantee Sustainable High Growth

​WinHealth's multi-engine BD model boosts ability to acquire innovative drugs, with short -term growth driven by acquisitions of Kyowa Kyrin, but...

Xinyao (Criss) Wang

HK Short Interest Weekly: Zto Express, HSBC, Hua Hong Semiconductor, Techtronic

We analyzed the latest HK SFC report for aggregate short position as of Feb 6th and highlight short interest changes in Zto Express, HSBC, Hua Hong...

Ke Yan, CFA, FRM

HK Connect Flows Weekly (Feb 13th): Tencent, Alibaba, Meituan, China Life, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Alibaba, Meituan, China Life, CNOOC.

Ke Yan, CFA, FRM

Pre-IPO Ming Yu Pharmaceutical - Popular Products Do Not Necessarily Guarantee Commercial Success

All core pipelines of Ming Yu face fierce competition, without commercialized products on the market.Success hinges on R&D resources and...

Xinyao (Criss) Wang

Quiddity Leaderboard HSCEI Mar26: One Index Change Likely; Announcement Soon

We see China Mengniu Dairy Co (2319 HK) as a high-conviction DEL and Horizon Robotics (9660 HK) as the replacement ADD in March 2026.

Janaghan Jeyakumar, CFA

WinHealth's multi-engine BD model boosts ability to acquire innovative drugs, with short -term growth driven by acquisitions of Kyowa Kyrin, but...